Contrasting Orgenesis (NASDAQ:ORGS) and Graybug Vision (NASDAQ:GRAY)

Earnings & Valuation

This table compares Orgenesis and Graybug Vision”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662,000.00	4.61	-$55.36 million	($11.51)	-0.05
Graybug Vision	$426.96 million	0.00	-$35.60 million	($24.23)	-0.03

Graybug Vision has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Orgenesis has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Orgenesis and Graybug Vision’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Graybug Vision	N/A	-77.61%	-71.34%

Summary

Graybug Vision beats Orgenesis on 6 of the 11 factors compared between the two stocks.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.